|
Asgary, S., Naderi, G., Sarrafzadegan, N., et al. (1999) Anti-oxidant effect of flavonoids on hemoglobin glycosylation. Pharmaceutica Acta Helvetiae 73, 223-226.
Baynes, J.W. (1991) Role of oxidative stress in development of complications in diabetes. DIABETES 40, 405-412.
Berg, T.J., Bangstad, H.J., Torjesen, P.A., Osterby, R., Bucala, R. & Hanssen, K.F. (1997) Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 46, 661-665.
Birrell, A.M., Heffernan, S.J., Ansselin, A.D., et al. (2000) Functional and structural abnormalities in the nerves of Type I diabetic baboons: Aminoguanidine treatment does not improve nerve function. Diabetologia 43, 110-116.
Brownlee, M. (2000) Negative consequences of glycation. Metabolism: Clinical and Experimental 49, 9-13.
Brownlee, M., Vlassara, H. & Cerami, A. (1985) Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 34, 938-941.
Brownlee, M., Vlassara, H. & Cerami, A. (1986) Trapped immunoglobulins on peripheral nerve myelin from patients with diabetes mellitus. Diabetes 35, 999-1003.
Bucala, R. (1997) Lipid and lipoprotein modification by advanced glycosylation end-products: Role in atherosclerosis. Experimental Physiology 82, 327-337.
Bucala, R., Makita, Z., Vega, G., et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proceedings of the National Academy of Sciences of the United States of America 91, 9441-9445. Ceriello, A., Giugliano, D., Quatraro, A., Donzella, C., Dipalo, G. & Lefebvre, P.J. (1991) Vitamin E reduction of protein glycosylation in diabetes: New prospect for prevention of diabetic complications? DIABETES CARE 14, 68-72.
Chibber, R., Molinatti, P.A., Rosatto, N., Lambourne, B. & Kohner, E.M. (1997) Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy. Diabetologia 40, 156-164.
Cooper, M.E., Thallas, V., Forbes, J., et al. (2000) The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 43, 660-664.
Cotlier, E. (1981) Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined to diabetes. INT. OPHTHALMOL. 3, 173-177.
Duraisamy, Y., Slevin, M., Smith, N., et al. (2001) Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: Possible relevance to wound healing in diabetes. Angiogenesis 4, 277-288.
Edelstein, D. & Brownlee, M. (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. DIABETES 41, 26-29.
Ellis, E.N. & Good, B.H. (1991) Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40, 1016-1019.
Gomez-Perez, F.J., Valles-Sanchez, V.E., Lopez-Alvarenga, J.C., et al. (1996) Vitamin E modifies neither fructosamine nor HbA1c levels in poorly controlled diabetes. Revista de Investigacion Clinica 48, 421-424.
Goova, M.T., Li, J., Kislinger, T., et al. (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. American Journal of Pathology 159, 513-525.
Hedrick, C.C., Thorpe, S.R., Fu, M.X., et al. (2000) Glycation impairs high-density lipoprotein function. Diabetologia 43, 312-320.
Hudson, B.I., Bucciarelli, L.G., Wendt, T., et al. (2003) Blockade of receptor for advanced glycation endproducts: A new target for therapeutic intervention in diabetic complications and inflammatory disorders. Archives of Biochemistry and Biophysics 419, 80-88.
Lewis, B.S. & Harding, J.J. (1990) The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins. Experimental Eye Research 50, 463-467.
Lopes-Virella, M.F., Klein, R.L., Lyons, T.J., Stevenson, H.C. & Witztum, J.L. (1988) Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. DIABETES 37, 550-557.
Makita, Z., Bucala, R., Rayfield, E.J., et al. (1994) Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. The Lancet 343, 1519-1522.
Makita, Z., Vlassara, H., Rayfield, E., et al. (1992) Hemoglobin-AGE: A circulating marker of advanced glycosylation. SCIENCE 258, 651-653.
McCance, D.R., Dyer, D.G., Dunn, J.A., et al. (1993) Maillard reaction products and their relation to complications in insulin- dependent diabetes mellitus. Journal of Clinical Investigation 91, 2470-2478.
Miyauchi, Y., Shikama, H., Takasu, T., et al. (1996) Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats. European Journal of Endocrinology 134, 467-473.
Monnier, V.M., Sell, D.R., Nagaraj, R.H., et al. (1992) Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. DIABETES 41, 36-41.
Nakamura, N., Hasegawa, G., Obayashi, H., et al. (2003) Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Research and Clinical Practice 61, 93-101.
Neumann, A., Schinzel, R., Palm, D., Riederer, P. & Mu?nch, G. (1999) High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-?B activation and cytokine expression. FEBS Letters 453, 283-287.
Niwa, T., Katsuzaki, T., Miyazaki, S., et al. (1997) Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. Journal of Clinical Investigation 99, 1272-1280.
Obayashi, H., Nakano, K., Shigeta, H., et al. (1996) Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. Biochemical and Biophysical Research Communications 226, 37-41.
Okumura, M., Okuda, T., Nakamura, T. & Yajima, M. (1996) Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. Biological and Pharmaceutical Bulletin 19, 530-535.
Ou, P. & Wolff, S.P. (1993) Aminoguanidine: A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochemical Pharmacology 46, 1139-1144.
Park, L., Raman, K.G., Lee, K.J., et al. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4, 1025-1031.
Peppa, M., Brem, H., Ehrlich, P., et al. (2003) Adverse Effects of Dietary Glycotoxins on Wound Healing in Genetically Diabetic Mice. Diabetes 52, 2805-2813.
Robert, B. & Harding, J.J. (1992) Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Experimental Eye Research 54, 509-518.
Santana, R.B., Xu, L., Chase, H.B., Amar, S., Graves, D.T. & Trackman, P.C. (2003) A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes 52, 1502-1510. Skolnik, E.Y., Yang, Z., Makita, Z., Radoff, S., Kirstein, M. & Vlassara, H. (1991) Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med. 174, 931-939.
Stern, D.M., Yan, S.D., Yan, S.F. & Schmidt, A.M. (2002) Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Research Reviews 1, 1-15. Stitt, A.W. (2003) The role of advanced glycation in the pathogenesis of diabetic retinopathy. Experimental and Molecular Pathology 75, 95-108.
Stopper, H., Schinzel, R., Sebekova, K. & Heidland, A. (2003) Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett 190, 151-156.
Sugiyama, S., Miyata, T., Horie, K., et al. (1996) Advanced glycation end-products in diabetic nephropathy. Nephrology Dialysis Transplantation 11, 91-94.
Szwergold, B.S., Kappler, F. & Brown, T.R. (1990) Identification of fructose 3-phosphate in the lens of diabetic rats. SCIENCE 247, 451-454.
Tanaka, N., Yonekura, H., Yamagishi, S.I., Fujimori, H., Yamamoto, Y. & Yamamoto, H. (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-[alpha] through nuclear factor-[kappa]B, and by 17[beta]-Estradiol through sp-1 in human vascular endothelial cells. Journal of Biological Chemistry 275, 25781-25790.
Tanji, N., Markowitz, G.S., Fu, C., et al. (2000) Expression of advanced glycation end products and their cellular receptor RAGE diabetic nephropathy and nondiabetic renal disease. Journal of the American Society of Nephrology 11, 1656-1666.
Thornalley, P.J. (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Archives of Biochemistry and Biophysics 419, 31-40.
Vasan, S., Foiles, P. & Founds, H. (2003) Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Archives of Biochemistry and Biophysics 419, 89-96.
Vasan, S., Zhang, X., Zhang, X., et al. (1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382, 275-278.
Vlassara, H. (1996) Advanced glycation end-products and atherosclerosis. Annals of Medicine 28, 419-426.
Vlassara, H., Brownlee, M. & Cerami, A. (1985) Recognition and uptake of human diabetic peripheral nerve myelin by macrophages. DIABETES 34, 553-557. Vlassara, H., Brownlee, M. & Cerami, A. (1988) Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. DIABETES 37, 456-461.
Vlassara, H., Striker, L.J., Teichberg, S., Fuh, H., Yong Ming, L. & Steffes, M. (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proceedings of the National Academy of Sciences of the United States of America 91, 11704-11708.
Yamagishi, S.I., Amano, S., Inagaki, Y., et al. (2002) Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochemical and Biophysical Research Communications 290, 973-978.
Yamamoto, Y., Kato, I., Doi, T., et al. (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. Journal of Clinical Investigation 108, 261-268.
Yan, S.D., Schmidt, A.M., Anderson, G.M., et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. Journal of Biological Chemistry 269, 9889-9897.
Yang, S., Litchfield, J.E. & Baynes, J.W. (2003) AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Archives of Biochemistry and Biophysics 412, 42-46.
|